Adverse drug reactions causing admission to a paediatric hospital. by Gallagher, RM et al.
Adverse Drug Reactions Causing Admission to
a Paediatric Hospital
Ruairi M. Gallagher1*, Jennifer R. Mason2, Kim A. Bird2, Jamie J. Kirkham3, Matthew Peak2,
Paula R. Williamson3, Anthony J. Nunn4, Mark A. Turner1, Munir Pirmohamed5, Rosalind L. Smyth1
1Department of Women’s and Children’s Health, University of Liverpool, Liverpool, United Kingdom, 2 Research and Development, Alder Hey Children’s Hospital NHS
Foundation Trust, Liverpool, United Kingdom, 3Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom, 4National Institute for Health Research
Medicines for Children Research Network, University of Liverpool, Alder Hey Hospital (previously: Department of Pharmacy, Alder Hey Children’s NHS Foundation Trust),
Liverpool, United Kingdom, 5Department of Pharmacology, University of Liverpool, Liverpool, United Kingdom
Abstract
Objective(s): To obtain reliable information about the incidence of adverse drug reactions, and identify potential areas
where intervention may reduce the burden of ill-health.
Design: Prospective observational study.
Setting: A large tertiary children’s hospital providing general and specialty care in the UK.
Participants: All acute paediatric admissions over a one year period.
Main Exposure: Any medication taken in the two weeks prior to admission.
Outcome Measures: Occurrence of adverse drug reaction.
Results: 240/8345 admissions in 178/6821 patients admitted acutely to a paediatric hospital were thought to be related to
an adverse drug reaction, giving an estimated incidence of 2.9% (95% CI 2.5, 3.3), with the reaction directly causing, or
contributing to the cause, of admission in 97.1% of cases. No deaths were attributable to an adverse drug reaction. 22.1%
(95% CI 17%, 28%) of the reactions were either definitely or possibly avoidable. Prescriptions originating in the community
accounted for 44/249 (17.7%) of adverse drug reactions, the remainder originating from hospital. 120/249 (48.2%) reactions
resulted from treatment for malignancies. The drugs most commonly implicated in causing admissions were cytotoxic
agents, corticosteroids, non-steroidal anti-inflammatory drugs, vaccines and immunosuppressants. The most common
reactions were neutropenia, immunosuppression and thrombocytopenia.
Conclusions: Adverse drug reactions in children are an important public health problem. Most of those serious enough to
require hospital admission are due to hospital-based prescribing, of which just over a fifth may be avoidable. Strategies to
reduce the burden of ill-health from adverse drug reactions causing admission are needed.
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Introduction
Children are vulnerable to adverse drug reactions (ADRs).
[1,2,3,4,5,6] Spontaneous reporting systems, such as the UK
Yellow Card scheme, [7] are subject to under reporting of ADRs,
even those which are severe. [8] To obtain reliable information
about the incidence of ADRs prospective studies are needed. A
systematic review of observational studies of ADRs causing
paediatric hospital admissions, between 1976 to 1996, estimated
the rate of ADR admissions to be 2.1% (95% CI 1.0, 3.8). [9] A
further review of prospective paediatric studies published between
2001 and 2007 did not identify any large studies of the incidence
and nature of ADRs causing hospital admission. [10]
Some results of the present study, prior to publication, were
included in a recent systematic review by Smyth et al in 2011 [11].
The authors reviewed prospective studies researching ADRs in
three settings; ADRs in-patients, those causing acute admission to
hospital and those occurring in out-patients. Incidence rates for
ADRs causing hospital admission ranged from 0.4% to 10.3% of
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all children (pooled estimate of 2.9% (2.6%, 3.1%)). Only 19/102
studies, from all three settings, assessed avoidability.
The aim of this study was to prospectively identify ADRs in
children causing hospital admission during a one year period in
order to quantify the burden of ADRs and characterise their
features. The investigators aimed to determine the avoidability of
identified ADRs and detail the reasons for determining reactions
as avoidable. This aspect of ADRs causing admission in children
has not been fully addressed in previous studies.
Methods
We prospectively screened all unplanned admissions to a tertiary
paediatric hospital for ADRs over a one year period, including
weekends and holidays, from 1st July 2008 to 30th June 2009.
Admissions were excluded if they were planned, or occurred as
a result of accidental or intentional overdose. Patients admitted to
an Accident and Emergency (A&E) department short-stay
‘observation ward’ were not included. [12] The definition of
ADR used was that of Edwards and Aronson which is ‘‘an
appreciably harmful or unpleasant reaction, resulting from an
intervention related to the use of a medicinal product, which
predicts hazard from future administration and warrants pre-
vention or specific treatment, or alteration of the dosage regimen,
or withdrawal of the product.’’ [13] This definition was chosen as
it describes only clinically significant adverse reactions that cause
harm and it includes the concept of preventive action.
Before the study began, an educational program was un-
dertaken amongst clinicians of all grades to raise awareness about
the importance of taking detailed medication histories. A
structured medication history section was added to medical
admission documentation to ensure details were taken about
medication in the preceding two weeks. We identified all
unplanned admissions in the previous 24 hours daily from hospital
information systems. The study team collected the following
information from case notes: age, sex, presenting complaint,
clinical history, diagnosis (if available), and medications, including
over-the-counter drugs, taken in the preceding two weeks. If any
information was unclear, study team members interviewed the
family to clarify the history.
We cross-referenced presenting symptoms/signs against the
medication history for each patient using the ADR profile for
relevant drugs from the Summary of Product Characteristics
(SPC) [14] in the Medicines Compendium or, if not available, the
British National Formulary (BNF) [15]. We identified possible
ADRs using this information combined with the clinical history
and temporal relationships of the medication(s) taken. We reported
all possible ADRs to the responsible clinicians and to the Yellow
Card scheme.
We assessed the origin of prescription for drugs thought to be
associated with ADRs using classifications of:
N Community – drugs where prescriptions originated in commu-
nity settings, for example general practice, or where admin-
istration took place prior to hospital admission (e.g. paramedic
administered)
N Hospital – drugs where the prescription originated, or
administration took place, in hospital and then may or may
not have been continued in community or outpatient settings
N Oncology – all drugs prescribed, or administered, from the
oncology ward.
Drug class, according to BNF classification, was recorded for
drugs implicated in causing ADRs. We performed assessment of
causality using the Liverpool ADR Causality Assessment Tool, an
algorithm developed by the investigators. [16] A novel aspect of
the tool, which allows for a case to be classified as ‘definite’
Table 1. Univariate analyses of ADRs by age.
Age (years, months)
[Median; Q1, Q3] All No ADR ADR Mann–Whitney U P–value
All [3y 1m; 9m, 9y] (n = 4656) [3y 0m; 9m, 9y] (n = 4514) [6y 0m; 2y 4m, 11y] (n = 142) 244161 ,0.001
Oncology [6y; 3y 6m, 12y] (n = 74) [6y; 3y 6m, 13y] (n = 33) [6y; 3y 0m, 10y] (n = 41) 580.5 0.296
Non–Oncology [3y; 9m, 9y] (n = 4582) [2y 11m; 9m, 9y] (n = 4481) [6y; 1y 7m, 11y] (n = 101) 178319.5 ,0.001
doi:10.1371/journal.pone.0050127.t001
Table 2. Univariate analyses of ADRs by number of medicines taken.
Drug Count [Median; Q1, Q3] All No ADR ADR Mann–Whitney U P–value
All [2;1,3] (n = 4656) [2;1,3] (n = 4514) [6;3,9] (n = 142) 115391.5 ,0.001
Oncology [6;4,9] (n = 74) [4;3,7] (n = 33) [8;5,10] (n = 41) 380.5 0.001
Non–Oncology [2;1,3] (n = 4582) [2;1,3] (n = 4481) [5;3,9] (n = 101) 100371.5 ,0.001
doi:10.1371/journal.pone.0050127.t002
Table 3. Multivariate logistic regression analysis for risk
factors for occurrence of ADR admission.
Parameter Odds Ratio (OR) 95% CI for OR P–value
Gender 0.77 0.52, 1.12 0.17
Age 1.04 1, 1.08 0.03
Oncology 29.71 17.35, 50.88 ,0.01
Number of medicines 1.24 1.19, 1.29 ,0.01
aVariable(s) entered on step 1: Gender (Male), Age, Oncology, Number of
medicines.
doi:10.1371/journal.pone.0050127.t003
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causality, is that prior drug exposure that led to the same ADR was
judged as being equivalent to a prospective re-challenge. Three
investigators (RG, MT, AN) independently assessed causality for
all ADR cases. Agreement on causality between all three
investigators was taken as accepted consensus. Where the
investigators did not achieve consensus, a fourth investigator
(MuP) assessed cases to decide on causality.
The investigating group met to assess avoidability of the ADRs
by consensus using the definitions developed by Hallas et al. [17]
We determined the type of ADR (using the Rawlins and
Thompson classification) [18] and severity using the Hartwig
scale. [19] We chose these assessment tools to describe the ADRs
in our study as they have been used in ADR studies by other
investigators and can be completed quickly. Three investigators
(AN, MuP, RLS) independently assessed 217/4514 (4.8%) reports
of admissions exposed to medication, but deemed not to have had
an ADR, to assess for occurrence of possible ADR cases wrongly
classified by the study team.
We calculated the mean cost of ADR admissions to the study
hospital, using information provided by the finance department for
the cost of each case. Paediatric emergency admission data from
the Health and Social Care Information Centre (National Health
Service (NHS)), between 2009/2010, was used to estimate the total
cost of ADR admissions annually in England.
Ethics Statement
The Liverpool Paediatric Research Ethics Committee issued
a formal opinion that this study was audit and informed consent
from individual patients was not necessary.
Statistical Analysis
Analyses of the rates of ADRs were based on the number of
admissions with the rate expressed as ADR per 100 admissions,
together with 95% confidence intervals. Other results are
presented as medians and interquartile ranges or percentage
frequencies and 95% percent confidence intervals. The formal
statistical analysis was based on the data obtained at the first
admission for patients exposed to a medication. Univariate
statistical analyses were performed using the Mann-Whitney U
test except for frequency data, which were analysed using a chi-
square test. A multivariate logistic regression analysis was un-
dertaken to calculate odds ratios for possible risk factors for ADR.





Cytotoxics (110) 275 Vincristine 51, Doxorubicin 38, Methotrexate 35, Etoposide 30,
Mercaptopurine 27, Cytarabine 24, Ifosfamide 18, Cyclophosphamide
15, Carboplatin 7, Vinblastine 5, Pegasparaginase 5, Dactinomycin 5,
Daunorubicin 4, Cisplatin 3, Irinotecan 3, Temozolomide 2,
Fludarabine 1, Amsacrine 1, Imatinib 1
Neutropenia 89, Thrombocytopenia 55, Anaemia 38,
Vomiting 8, Mucositis 8, Deranged Liver Function Tests 7,
Immunosuppression 7, Diarrhoea 5, Nausea 4,
Constipation 3, Headache 2, Abdominal pain 1, Back pain
1, Haematuria 1, Leukencephalopathy 1, Deranged renal
function 1
Corticosteroids (102) 107 Dexamethasone 68, Prednisolone 33, Hydrocortisone 2,
Betamethasone 1, Mometasone 1,
Methylprednisolone 1, Fluticasone 1
Immunosuppression 71, Post–op bleeding 23,
Hyperglycaemia 3, Hypertension 1, Gastritis 1, Increased
appetite 1, Impaired healing 1, Adrenal suppression 1
NSAIDs (31) 43 Ibuprofen 28, Diclofenac 15 Post–op bleeding 27, Haematemesis 2, Constipation 1,
Abdominal pain 1
Vaccines (22) 37 Diphtheria Tetanus Pertussis Inactivated polio Haemophilus
Influenza vaccine 11, Pneumococcal conjugate 9,
Meningococcal C 8, MMR 7, Haemophilus Influenza B 1, Influenza 1
Fever 8, Rash 5, Irritability 4, Seizure 4, Vomiting 3, Pallor 1,
Apnoea 1, Limb swelling 1, Lethargy 1, Thrombocytopenia




26 Tacrolimus 15, Mycophenolate 7, Azathioprine 2,
Methotrexate 1, Infliximab 1
Immunosuppression 18
Anti–bacterial (16) 17 Co–amoxiclav 4, Penicillin V 3, Amoxicillin 3, Flucloxacillin 2,
Cefaclor 1, Cefalexin 1, Cefotaxime 1, Teicoplanin 1, Erythromycin 1
Diarrhoea 7, Rash 4, Vomiting 4, Lip swelling 1, Deranged
LFTs 1, Thrush 1
Drugs used in
diabetes (9)
13 Insulin detemir 4, Insulin aspart 3, Isophane insulin 2,
Biphasic isophane 2, Human insulin 2,
Hypoglycaemia 9
Drugs used in status
epilepticus (8)
12 Lorazepam 5, Diazepam 5, Midazolam 2 Respiratory depression 8
Opioid analgesia (6) 7 Dihydrocodeine 3, Codeine phosphate 3, Fentanyl 1 Constipation 4, Ileus 1, Decreased conscious level 1
Drugs used in nausea (4) 4 Ondansetron 4 Constipation 4
Anti–epileptic drugs (2) 2 Carbamazepine 1, Nitrazepam 1 Constipation 1, Respiratory depression 1
Drugs that suppress
rheumatic disease (2)
2 Methotrexate 1, Anakinra 1 Immunosuppression 2
Other (16) 4 Calcium carbonate and Amlodipine 1, Oxybutynin 1, Baclofen 1 Constipation 3
2 Dimeticone 1, Carbocysteine 1 Rash 2
2 Desmopressin acetate 1, Alimemazine 1 Seizure 2
10 Glucose and Dextrose 1, Propanolol 1, Acetazolomide 1,
Spironolactone 1, Loperamide 1, Macrogols 1, Captopril 1,
Alfacalcidol 1, Ethinylestradiol 1
Hyperglycaemia 1, Wheeze/Difficulty in breathing 1,
Headache 1, Hyperkalaemia 1, Intestinal obstruction 1,
Diarrhoea 1, Renal dysfunction 1, Hypercalcaemia 1, Inter–
menstrual bleed 1
doi:10.1371/journal.pone.0050127.t004
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A P-value ,0.05 was regarded as being significant. All data were
analyzed anonymously.
Results
Over the study period, there were 6821 patients (3961 boys and
2860 girls) admitted 8345 times to the study hospital. The median
number of admissions per patient was one, with 932 patients
having more than one acute admission, up to a maximum of
fifteen. 178 patients (94 boys, 84 girls) experienced 240 admissions
with an ADR. This gives an incidence of 2.9 ADRs per 100
admissions (95% CI 2.5, 3.3). In 233 of 240 (97.1%) admissions an
ADR was deemed to have directly caused, or contributed to,
admission. There were 249 ADRs in 240 admissions, with nine
admissions having two separate ADRs. 35/178 (19.7%) patients
Figure 1. Number of ADRs per patient with $ one ADR according to origin of prescription.
doi:10.1371/journal.pone.0050127.g001
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had more than one admission (maximum seven) with an ADR.
Assessment of a sample of non-ADR cases (n = 217) confirmed that
no admissions were due to ADRs.
There were 4656 patients exposed to medication in the two
weeks prior to acute hospital admission. Of these, 142 (3%) had
a suspected ADR on their first hospital admission. There was no
significant difference between the proportion of boys (76/2677,
2.8%) and girls (66/1979, 3.3%) experiencing an ADR on their
first admission, for the group as a whole or oncology patients
studied separately. For non-oncology patients, there was a slightly
higher proportion of girls admitted with an ADR (boys 48/2627
Table 5. Possibly and definitely avoidable cases and explanation of assessment result.
Avoidable Frequency ADR(s) Drug Classes Reason for potential avoidability
Definitely 3 Diarrhoea and/or vomiting Anti-bacterial Inappropriate indication, signs/symptoms of
viral illness
Definitely 2 Constipation Cytotoxics, Drugs used in nausea,
Opioid analgesia
Appropriate prophylaxis not used
Definitely 1 Lip swelling, rash Anti-bacterial Same ADR previously to same medication
Definitely 1 Seizure Antihistamine Same ADR previously to similar medication
Definitely 1 Adrenal suppression Corticosteroids Avoidable with more rational prescribing
(prolonged use of drugs) and improved
monitoring
Definitely 1 Intestinal obstruction Anti-motility drugs Could be prevented by improved parent/
patient education
Definitely 1 Deranged renal function Drugs affecting the renin-
angiotensin system
Avoidable with improved monitoring
Possibly 9 Hypoglycaemia Drugs used in diabetes Avoidable with improved patient education
(e.g. insulin use when unwell) and more
rational prescribing
Possibly 8 Respiratory depression Drugs used in status epilepticus, Hypnotics Alternative medicine available, Multiple doses
given - avoidable with more rational
prescribing
Possibly 6 Diarrhoea/vomiting Anti-bacterial Inappropriate indication, symptoms suggested
viral infection
Possibly 5 Constipation Antiepileptic drugs, Opioid analgesia,




Possibly 4 Immunosuppression Drugs affecting the immune
response, Corticosteroids
Possibly Avoidable with improved monitoring
of drug levels, Avoidable with more rational
prescribing
Possibly 2 Haematemesis NSAIDs Avoidable with improved patient education/
more rational prescribing (less NSAID use)




Cytotoxics Superficial infection after recent admission
with febrile neutropenia. Possibly avoidable by
prolonging antibiotic use or commencing
GCSF
Possibly 1 Hyperglycaemia Corticosteroids Avoidable with more rational prescribing
(prolonged course steroids used)
Possibly 1 Hyperglycaemia Parenteral preparations Avoidable with more rational prescribing
(more judicial use) or improved monitoring
Possibly 1 Seizure Posterior pituitary hormones Possibly inappropriate medication used for
a patient with seizures
Possibly 1 Diarrhoea Laxatives Avoidable with improved patient education
Possibly 1 Ileus Opioid analgesia Avoidable with more rational prescribing
(possibly use alternative analgesia)
Possibly 1 CNS depression Opioid analgesia Avoidable with improved patient education
Possibly 1 Vomiting Cytotoxics Possibly avoidable with more appropriate anti-
emetic prophylaxis
Possibly 1 Gastritis Corticosteroids Previous gastritis. Possibly avoidable with
improved prophylaxis
Possibly 1 Hypercalcaemia Vitamins Avoidable with improved monitoring
doi:10.1371/journal.pone.0050127.t005
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(1.8%), girls 53/1955 (2.7%), P = 0.044), although overall more
boys than girls were admitted.
The median age of the 4656 patients who had been exposed to
a drug on their first admission was 3 years 1 month (IQR 9
months, 9 years). Patients with an ADR (6y; 2y 4m, 11y) were
significantly older (P,0.01) than those without (3y; 9m, 9y)
(Table 1). There was no age difference between 41 oncology
patients admitted with an ADR (6y; 3y, 10y) and 33 oncology
patients admitted without an ADR (6y; 3y 6m, 13y). There was
a significant age difference (P,0.01) between 101 non-oncology
patients admitted with ADR (6y; 1y 7m, 11y) and 4481 admitted
without ADR (2y 11m; 9m, 9y).
Patients admitted with an ADR had taken a greater number of
drugs than those admitted for other reasons (Table 2). For patients
admitted with an ADR (n= 142), the number of medicines taken
was higher (6; 3, 9, P,0.001) than those for other reasons
(n = 4514) (2; 1, 3). The number of medicines taken by oncology
patients admitted with an ADR (8; 5, 10) was higher than those
admitted without an ADR (4; 3, 7) and this difference was also
found for non-oncology patients (with ADR 5; 3, 9: without ADR
2; 1, 3).
Logistic regression analysis showed a trend towards boys being
less likely to experience an ADR than girls, with an odds ratio
(OR) of 0.77 (95% CI 0.52, 1.12, P= 0.17) (Table 3). There was an
increased likelihood of ADRs with increasing age (OR 1.04, 95%
CI 1.003, 1.08, P = 0.03). No children were admitted with an
ADR in the first month of life. Oncology patients were much more
likely to have an ADR causing admission (OR 29.71, 95% CI
17.35, 50.88, P,0.001). The likelihood of a child being admitted
with an ADR increased with the number of medicines taken (OR
1.24, 95% CI 1.19, 1.29, P,0.001). Therefore, for each additional
medicine taken the risk of an ADR occurring increases by almost
25%.
Drug Class
The main class of drugs contributing to ADR-related admissions
(n = 110; 44.2%) was cytotoxic drugs (Table 4). Corticosteroids
(n = 102, 41%), non-steroidal anti-inflammatory drugs (NSAIDs)
(n = 31, 12.4%), vaccines (n = 22, 8.8%) and immunosuppressants
(n = 18, 7.2%) were the next most commonly implicated drug
classes causing ADR-related hospital admissions.
ADRs
The most common ADRs were oncology related including
neutropenia (89), thrombocytopenia (55) and anaemia (38). The
next most common ADR was immunosuppression (74), occurring
in both oncology and non-oncology patients. Post-operative
bleeding, linked to peri-operative corticosteroid administration
and/or NSAIDs, caused 28 admissions (26 post-tonsillectomy).
Vomiting (15), diarrhoea (14), rash (11) and constipation (9) were
all common ADRs causing admission. Hypoglycaemia in diabetic
patients treated with regular insulin caused nine admissions.
Respiratory depression following treatment for status epilepticus
caused eight admissions to the hospital’s paediatric intensive care
unit (PICU).
Origin of Prescriptions
44/249 (17.7%) of ADRs were associated with prescriptions
from the community, 85/249 (34.1%) with prescriptions originat-
ing in hospital for treatment of conditions other than oncology;
120/249 (48.2%) with prescriptions originating from oncology. Of
the patients with one ADR (n= 140) in the study period, 39
(27.9%) occurred with community prescriptions, 71 (50.7%) with
hospital prescriptions and 30 (21.4%) with oncology prescriptions;
hospital-based prescriptions, particularly oncology, predominated
in patients who had more than one ADR (Figure 1).
ADR Assessments (Reaction Type, Causality, Severity,
Avoidability)
238/249 (95.6%) ADRs were classified as type A (predictable
from the known pharmacology) with 11/249 (4.4%) being type B
(not predictable). Assessment of causality showed the majority of
cases (94/249, 37.8%) to be in the ‘definite’ category. Oncology
cases accounted for 80 of these 94 definite cases (Table S1). 92/
238 (39.1%) type A reactions were assessed to be of definite
causality. 8/11 (72.7%) type B reactions were assessed to be
‘possible.’
223/249 (89.6%) of the ADRs were classified as grade 3
(‘required treatment or drug administration discontinued’) accord-
ing to the Hartwig severity scale, as we defined anyone requiring
admission to hospital as ‘needing treatment.’ 14 (5.6%) were
classified as grade 4 (‘resulted in patient transfer to higher level of
care’) including respiratory depression (8), immunosuppression (4),
neutropenia (1), fever/seizure (1) and leukencephalopathy (1).
Three ADRs were classified as grade 5 (‘caused permanent harm
or significant haemodynamic instability’). Two of these most
severe ADRs occurred in oncology patients with febrile neutro-
penia and septicaemia and the remaining case was a child who
required bowel resection for ileus following treatment with
loperamide. No ADRs contributed to death. The majority (16/
17, 94.1%) of the more severe reactions ($ Grade 4 Hartwig
severity score) were assessed to have definite or probable causality.
We determined 112/120 (93.3%) of the oncology patient
admission ADRs to be unavoidable, with a further six being
possibly avoidable and two definitely avoidable. These ‘definitely
avoidable’ cases were oncology patients with constipation follow-
ing treatment with vincristine and ondansetron (with one also
having dihydrocodeine) without laxative prophylaxis.
Of the ADR admissions not associated with oncology patients,
82/129 ADRs (63.6%) were classified as unavoidable, 39 (30.2%)
as possibly avoidable (14/39 prescribed from the community) and
8 (7.6%) as definitely avoidable (5/8 prescribed from the
community). The eight ‘definitely avoidable’ comprised four
patients prescribed antibiotics where the antibiotic choice or
indication was deemed to be inconsistent with good practice, one
patient with intestinal obstruction being treated with loperamide
who had not passed stool for two days prior to admission, one
patient who had a seizure after alimemazine having had two
previous occurrences of seizure following anti-histamine use, one
patient with deranged renal function which improved after
cessation of captopril where improved renal function monitoring
may have avoided the ADR, and one patient who presented with
adrenal suppression following two years of continuous treatment
with intranasal corticosteroids. The possibly avoidable cases and
the reasons for their allocation are summarised in Table 5. 41/55
(74.5%) of possibly or definitely avoidable cases were classified as
‘definite’ or ‘probable’ causality.
Cost of ADRs
We calculated the mean cost of 238/240 ADR admissions to the
study hospital, using information provided by the finance de-
partment, to be £4753 per admission (95% CI £3439, £6066).
Cost data were missing for two ADR admissions. Data from the
Health and Social Care Information Centre (National Health
Service (NHS)) [20] showed, in one year between 2009/2010, the
total number of paediatric emergency admissions in England was
approximately 597,800 (includes paediatrics and paediatric
surgery, cardiology and neurology). We estimate the annual mean
Drug Reactions Causing Paediatric Admission
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cost of ADR admissions to the NHS in England to be £82.4M.
Using the upper and lower confidence intervals for our estimate of
ADR incidence (2.5%, 3.3%), and study hospital costs, we estimate
the cost to the NHS in England to be between £51.4–119.7M.
Discussion
This prospective observational study is the largest of its kind in
children and the only one to comprehensively assess causality, type
of reaction, severity, avoidability and risk factors. In our setting,
the majority of admissions associated with ADRs in children
occurred as a result of prescriptions originating in hospital.
Potential preventative strategies for ADRs causing admission in
children should therefore be targeted at hospital prescribing. Our
analysis of the ‘definitely avoidable’ ADRs in our study suggests
careful attention to practical aspects of care, such as improved
monitoring, following prescribing guidelines, patient education,
and heightened suspicion about potential reactions could lead to
a reduction in the frequency of this important problem.
This study gave an estimated ADR admission incidence of 2.9%
(95% CI 2.5, 3.3), which is similar to a pooled estimate of 2.9%
(2.6%, 3.1%) from a recent comprehensive systematic review. [11]
The incidence of ADRs in this study was significantly less than that
of a large US study published in 1988 (3.96%, 95%CI 3.52, 4.43).
[2] In that study the top three drugs causing ADRs were
phenobarbital, aspirin and phenytoin, all of which are used in
children much less now because of safety concerns and because
better alternatives are available. The majority of ADRs that were
seen during our study were oncology related. Oncology patients
are often exposed to medications causing ADRs, including
neutropenia, nausea, vomiting, diarrhoea and thrombocytopenia,
all of which may require admission. [21] These ADRs are
expected and may be unavoidable given the underlying illness and
the treatment options available. Although several studies have
evaluated a potential preventative strategy for neutropenia [22],
no definite evidence exists regarding the use of granulocyte-colony
stimulating factors (GCSF) to prevent such ADRs [23].
Steroids, along with other immunosuppressants, increase risk of
infection. [24] These ADR admissions were children taking
steroids, admitted with proven bacterial, or viral infections
associated with immunosuppression, such as shingles. Although
such infections occur in healthy children, immunosuppressive
therapy may be causal and this may be an under-recognised ADR.
The majority of admissions for post-operative bleeding (23/28)
occurred in patients exposed to intravenous dexamethasone for
anti-emetic prophylaxis, and non-steroidal anti-inflammatory
drugs (NSAIDs). A few patients received either steroid or NSAIDs.
Dexamethasone has been linked to post-tonsillectomy bleeding
[25] but its role, and the role of NSAIDs, in causing secondary
haemorrhage is yet to be determined. [26,27] However, intra-
operative steroids have played a major role in improving post-
operative nausea and vomiting in children. [26,28]
Respiratory depression following treatment of seizures with
benzodiazepines, a well recognised event, [29] was the cause of
eight PICU admissions, some of whom were transfers from other
district general hospitals. Some occurred as a result of rectal
diazepam used by paramedics in out-of-hospital care. The benefit/
risk ratio of drugs used to treat seizures has been the objective of
a number of clinical studies [30,31], and there may be better drugs
to treat seizures in children. [32]
Assessment of avoidability was undertaken by consensus
approach using the definitions by Hallas. The definitions, which
are based on avoidability linked to standards of care, are wide and
may lead to variability in assessor rating. The Hallas criteria are
less prescriptive than some other avoidability tools but there is little
evidence to suggest preference for the use of any one avoidability
tool. [33]
While this study has highlighted important ADRs, we cannot be
certain of the aetiological fraction (the risk of an event occurring in
the presence of a risk factor) for some of the drugs in their
contribution to the ADRs. Further prospective, cohort studies that
capture benefits and harms using validated tools and all
medication exposures with adequate sample size are needed to
assess this accurately and to estimate more precisely risks
compared to benefits.
We calculated the cost of ADRs to the NHS in England using
knowledge of the cost of admissions to the study hospital, our
estimate of the incidence of ADRs causing admission and an
estimate of total paediatric admissions annually to hospitals in
England, although this may be an underestimate, as the multiplier
which we used (total paediatric emergency admissions), did not
include admissions of children from other specialities.
Conclusion
We have demonstrated that ADRs cause a small but substantial
proportion of admissions to hospital and some of these are serious
and potentially avoidable. The results of this study should be used
to inform paediatric pharmacovigilance practice. Preventing
avoidable ADRs will require careful attention to good prescribing
practice.
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